Where PBM Reform Stands Across the US

Why It Matters

The combined state and federal reforms promise greater pricing transparency and stronger support for independent pharmacies, while exposing PBMs to heightened compliance costs and legal risk.

Key Takeaways

• Arkansas' PBM ownership ban blocked by federal injunction
• California mandates pass‑through pricing and caps patient cost‑sharing
• Colorado adopts flat‑fee PBM model effective 2027
• Federal 2026 law forces PBMs to pass 100% rebates to plans
• Litigation over state PBM laws centers on ERISA and Commerce Clause

Pulse Analysis

Across the United States, lawmakers are converging on a common goal: curbing the opaque practices that have long allowed pharmacy benefit managers to inflate drug costs. From Arkansas’ attempted ban on PBM‑owned pharmacies to California’s strict pass‑through pricing rules, states are mandating flat‑fee structures, prohibiting spread pricing, and safeguarding independent pharmacies from steering mandates. These measures reflect a broader shift toward transparency, with many states also imposing reimbursement standards tied to average acquisition costs, thereby leveling the playing field for smaller retailers.

The reform wave, however, is not without legal turbulence. Federal courts have already halted Arkansas’ ownership ban on commerce‑clause grounds, and the Supreme Court’s recent refusal to review a decision striking down parts of Oklahoma’s law signals that preemption challenges will persist. ERISA and other federal statutes remain the primary battleground, as seen in ongoing disputes in Minnesota and Tennessee. Simultaneously, the 2026 Consolidated Appropriations Act marks the first substantive federal intervention, requiring PBMs to pass 100% of rebates to Medicare Part D plans and eliminating compensation tied to list prices, setting a national benchmark that could influence state legislation.

For the industry, the implications are profound. Independent pharmacies stand to gain market access and more predictable reimbursement, while health plans may see reduced drug spend volatility thanks to clearer rebate flows. PBMs, on the other hand, must redesign fee structures and invest in compliance infrastructure, potentially reshaping profit models. Patients could benefit from lower out‑of‑pocket costs as cost‑sharing aligns with actual acquisition prices. As state attorneys general rally behind transparency measures, the momentum suggests that PBM reform will continue to evolve, balancing consumer protection with the legal complexities of a fragmented regulatory landscape.